

Antibody Drug Conjugate (ADC) Services


With more than 10 Antibody-drug conjugates (ADCs) now approved by the FDA, ADC has become one of the most promising modalities for cancer therapy. In addition to linker and payload, having a suitable antibody is paramount for the development of successful ADCs. AvantGen's expertise in novel antibody discovery and its proprietary human antibody discovery technology platform makes us your ideal partner to speed up your ADC programs.

AvantGen's yeast display human antibody libraries are comprised of 25 libraries constructed based on comprehensive natural human antibody databases where the frequencies of each amino acid at each position of all 6 CDRs were determined based on deep sequencing of natural human antibody repertoires with more than 100 billion antibody clones displayed.



Case study: 45 unique antibody clones were isolated from our libraries that bind to BCMA. Some of them internalize more rapidly than J6M0, the antibody component of GlaxoSmithKline's belantamab mafodotin and exhibit more potent killing activity than J6M0 when conjugated to a payload (MAFF).

AvantGen Technology Platform	
Attributes	Performance
Diversity and Activity for Internalization	Typically, a panel of 10s-100s unique antibody clones can be isolated and screened further for clones that can trigger rapid internalization
Affinity and Specificity	The majority of antibody clones isolated from our libraries exhibit affinity in sub-nM to single digit nM range and are highly specific to the antigen of interest with or without cross reactivity to other homologous proteins or isoforms
Developability	Antibodies designed to be of high developability (described to the left of this table)
Humanness	Libraries rationally designed to mimic diversity in human antibody database compiled from >500 diverse individuals

High BCMA expressing cell line:
H929 (3 days)



Low BCMA expressing cell line:
MM.1S and RPMI8226 (6 days)



Antibody	H929 Cells		MM.1S Cells		RPMI8226 Cells	
	IC50 (nM)	Fold better than GSK-J6M0	IC50 (nM)	Fold better than GSK-J6M0	IC50 (nM)	Fold better than GSK-J6M0
AVG-A11	0.79	4.4	0.55	3.1	0.51	5.3
GSK-J6M0	3.5		1.7		2.7	

AvantGen's collaborations in the ADC area:

[Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates;](#)

[AvantGen and Tanabe Research Laboratories Expand Collaboration for Therapeutic Antibody Discovery](#)